PropertyValue
?:abstract
  • More than a million people have now died from COVID-19, because of infection with the SARS-CoV-2 coronavirus Currently, the FDA has approved remdesivir, an inhibitor of SARS-CoV-2 replication, to treat COVID-19, though very recent data from WHO showed little if any COVID19 protective effect Here we report that ethacridine, a safe and potent antiseptic use in humans, effectively inhibits SARS-CoV-2, at very low concentrations (EC 50 ~ 0 08 mu M) Ethacridine was identified through a high-throughput screening of an FDA-approved drug library in living cells using a fluorescent assay Interestingly, the main mode of action of ethacridine is to inactivate virus particles, preventing binding to the host cells Thus, our work has identified a potent drug with a distinct mode of action against SARS-CoV-2
is ?:annotates of
?:creator
?:journal
  • BioRxiv_:_the_Preprint_Server_for_Biology
?:license
  • unk
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:source
  • WHO
?:title
  • Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models
?:type
?:who_covidence_id
  • #915982
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/cydti2lu>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/cydti2lu>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all